核医学显像探针在肿瘤PD-L1免疫治疗中的应用

Application of Nuclear Imaging Probes in PD-L1 Immunotherapy of Tumor

程序化死亡配体-1(PD-L1)靶向免疫治疗被广泛应用于不同类型的癌症中,患者从PD-L1靶向免疫治疗的获益主要依赖于肿瘤组织PD-L1的表达水平。目前临床主要采用穿刺活检等有创手段来评价肿瘤组织PD-L1的表达水平,严重受限于PD-L1表达的时间和空间异质性。核医学探针能够在分子水平上实现对PD-L1的在体无创检测,对于指导患者筛选、预测患者免疫治疗响应具有重要的临床意义。本文综述了靶向PD-L1的核医学分子影像探针,并讨论其在肿瘤PD-L1显像中的应用。

Immunotherapy strategies of targeting PD-1 and its ligand PD-L1 are widely administered in varied types of cancer.Patient benefitting from PD-L1 targeted immunotherapy mainly depends on the expression level of PD-L1 in tumor tissues.Currently,the expression level of PD-L1 is primarily detected through the invasive method of biopsy in clinic,which is severely limited by the temporal and spatial heterogeneity of PD-L1 expression.Nuclear medicine probe can realize the noninvasive as well as in vivo detection of PD-L1 at the molecular level,which has important clinical significance for the guidance of patient screening and the prediction of patient's response to immunotherapy.This article reviews PD-L1 targeting nuclear imaging probes and their applications in tumor PD-L1 imaging.